Canada markets open in 9 hours 29 minutes

NervGen Pharma Corp. (NGEN.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
1.98000.0000 (0.00%)
At close: 03:49PM EDT
Sign in to post a message.
  • C
    Charlie
    NervGEN May 20 2022 The ‘International Investment Forum’

    https://www.youtube.com/watch?v=2S3vYP6Hj_c

    Unleashing the Nervous System to Repair and  Heal Itself- including multiple sclerosis (MS), Alzheimer’s disease, spinal cord injury, stroke and traumatic brain injury (TBI).
    3. IIF - NervGen Pharma Corp.
    www.youtube.com
  • J
    John
    March 30, 2022

    San Diego Torrey Hills Capital NervGEN Presentation

    https://www.youtube.com/watch?v=Nh-ENCcW1JE

    Unleashing the Nervous System to Repair and  Heal Itself- including multiple sclerosis (MS), Alzheimer’s disease, spinal cord injury, stroke and traumatic brain injury (TBI). $SAVA $CRTX
    NervGen Pharma - CEO Paul Brennan - March 30, 2022
    www.youtube.com
  • J
    John
  • J
    John
    Yesterday, we announced our plan to initiate our clinical trial for spinal cord injury (SCI) patients later this year. I would like to focus your attention on three highlights:

    we are including a “chronic” group of patients in this trial,
    we have strategically chosen to run a single site trial, and
    we are running our trial at Shirley Ryan AbilityLab in Chicago, voted the “No. 1 Rehabilitation Hospital in America” by U.S. News & World Report every year since 1991.

    Most clinical trials for drugs to treat spinal cord injuries target those with “acute” injuries, meaning they administer the drug to patients that suffered their injuries within hours or days. It is rare that a clinical trial includes a patient group that suffered their injury one year previously. We are enthused and justified to include a patient group that is ≥1-year post-injury based on the preclinical evidence we have collected. If we are able to achieve a meaningful level of functional improvement in this “chronic” group, this would be the first clinical evidence to give hope to the hundreds of thousands of people that have been suffering from a spinal cord injury for a long period of time.

    While there are several excellent, leading edge spinal cord injury treatment and rehabilitation facilities, Shirley Ryan AbilityLab’s combination of world-renowned expertise in the management of SCI patients, vast experience in monitoring recovery in SCI patients using sophisticated electrophysiology techniques and the large number of SCI patients that seek care at their facilities moved the hospital to the top of the list for this trial. And by restricting our trial to one center, we can include more sophisticated variables in our analyses that we would not be able to include in a multi-center trial.

    We are very confident that this very important relationship with Shirley Ryan AbilityLab will result in the most effective and expeditious clinical trial possible.

    About Shirley Ryan AbilityLab
    It is the global leader in physical medicine and rehabilitation for adults and children with the most severe, complex conditions – from traumatic brain and spinal cord injury to stroke, amputation and cancer-related impairment. The Shirley Ryan AbilityLab expands and accelerates leadership in the field that began at Rehabilitation Institute of Chicago in 1953 – its care and research designated it the “No. 1 Rehabilitation Hospital in America” by U.S. News & World Report every year since 1991. Upon opening in March 2017, the $550 million, 1.2 million square foot Shirley Ryan AbilityLab became the first-ever “translational” research hospital where clinicians, scientists, innovators and technologists work together in the same space, surrounding patients, discovering new approaches and applying (or “translating”) research in real time.

    I trust you will find this news release as compelling and important as we do. To learn more about our spinal cord injury program, click here.If you have any comments or questions, please do not hesitate to reach out to us directly.

    Sincerely,
    Paul Brennan
    President & CEO
  • J
    John
    NervGen New Alzheimer’s Disease drug begins Phase I clinical trial
    June 21, 2021 |




    For the more than six million Americans living with Alzheimer’s disease and the people who care for them there could be promising news.

    Although nearly one in every three people will eventually be afflicted and it’s the third leading cause of death of older adults in the U.S. (surpassed only by heart disease and cancer in non-pandemic years), there may be effective treatments on the horizon.

    Researchers are testing a new drug that may someday be used to treat Alzheimer’s disease.
    One contender is about to start a Phase I clinical trial. It’s a novel drug known as NVG-291 and it’s designed to repair damaged nerves. Originally developed by NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) to treat spinal cord injury, it soon became apparent that the drug may be healing nerve damage at a biologically fundamental level.

    That suggests it can also help people who have multiple sclerosis and Alzheimer’s disease.
    According to NervGen President & CEO Paul Brennan, NVG-291 is a truly unique and logical approach to treating Alzheimer’s disease patients.

    “What differentiates NVG-291 from other drugs in development is that it leverages multiple mechanisms for repairing nerve damage,” he explains, “While most others focus on a single approach. Alzheimer’s disease is a complex condition and likely caused by multiple factors. We believe that a systems approach to treating the disease is an important distinction.”

    NVG-291 is designed to achieve this by liberating the body’s own repair mechanisms to accelerate nerve repair. When nerve damage occurs, either as a result of an injury or disease, molecules called chondroitin sulfate proteoglycan, or CSPG, accumulate and inhibit the body’s ability to repair itself.

    NervGen’s technology is designed to counteract this inhibition and result in the initiation of multiple repair mechanisms, including nerve regeneration and remyelination – the repair of the protective coating of the nerves. It should also improve plasticity, which is where surviving nerves take on additional function.

    There are two additional mechanisms that are seen to be very important in treating Alzheimer’s disease. Data in animal studies show that inflammation in the immune cells of the brain is reduced and autophagy, a cellular cleaning mechanism necessary for healthy neurons, is promoted. Researchers believe the same nerve-rejuvenating biotechnology can be adapted to remedy this mind-desecrating disease.

    Currently approved Alzheimer’s disease drugs merely address symptoms, whereas NVG-291 should act at a more fundamental level to let normal repair mechanisms kick in to create a favorable environment for nerves to grow and form entirely new nerve connections, according to Brennan.

    The ability to bring to bear numerous mechanisms of repair, including two that are increasingly viewed as critical to addressing Alzheimer’s disease, represents an unprecedented medical breakthrough.


    https://www.clarksvilleonline.com/2021/06/21/new-alzheimers-disease-drug-begins-phase-i-clinical-trial/
  • M
    Mike
    This is a very big year for NervGen. I must admit, I never thought I would see the sp drop to the 1.80s ever again. If you are selling right now you are clearly not paying attention...
  • M
    Mark
    Every time this dips under $2 I try to buy some shares. I'm hoping for cures and success.
  • C
    Charlie
    https://twitter.com/NervgenP/status/1450469289182519313?t=M5CCKGRsXysRep1jjoFx8A&s=19

    Join BioPub founder Mark Swaim for a live webcast to discuss NervGen's Phase 1 data with NervGen's CEO, CMO and special guest, Dr. Jerry Silver. Click link to join. https://us02web.zoom.us/j/83730654372 Date: Wednesday, Oct 20, 2021 Time: 12:00pm EDT (9:00am PDT) #neuroscience #clinicaltrial
  • C
    Charlie
    NervGen aiming NVG-291 at treating spinal cord injury, multiple sclerosis and Alzheimer’s disease.

    Earlier this month, the company reported preliminary data from an ongoing Phase 1 trial, with iA Capital Markets analyst Chelsea Stellick reporting that the results show an excellent trajectory in the study’s first 25 subjects.

    “The pharmacokinetic data from cohorts one through four show a more favourable profile in humans than in rodents, including a longer half-life (detectable up to 12 hours post-dose) alongside rapid distribution in the blood. These signals are very encouraging since this means NVG-291 is likely to have an even stronger effect in humans than it had in rodents, all else equal. Given the profound efficacy already seen in rodents, these early signals exceeded our expectations and are very promising for the prospect of bringing NVG-291 to humans,” Stellick wrote in an October 18 update.
  • x
    x
    Yahoo Finance list average vol for NGENF as 30,000 and the days vol ended up over 500K. I wonder who sold? The stock was halted before they announced the closing of the bought deal which was set below the market price.

    The problem with this stock is the volume.
  • J
    John
    What makes NVG-291 different from other drugs in development in neurological disorders?

    Paul Brennan: There are multiple factors that differentiate NVG-291 from other drugs in development for neurological disorders.

    NVG-291’s mechanism of action works through repairing and restoring neurological function. Most other drugs in development in the CNS space are focused on slowing the progression of the disease, and most neurological diseases are very slowly progressing. With this differentiated approach, we should see a quicker response, and that response should be seen with fewer patients.

    Whereas most drugs in development have only one pharmacodynamic response, NVG-291 has a multi-modal mechanism of response (axon regeneration, increased plasticity, remyelination).

    The scope, pattern, and magnitude of response seen in functional studies with NVG-291 are broad and deep compared to other products in development. For example, firstly, NervGen believes it has the potential to be effective in any disorder where there is damage to the nervous system, whether acute or chronic. Secondly, NVG-291 demonstrates pharmacological activity across the major neurological functions (autonomic function, sensory function, cognition, and motor control). And thirdly, in some experiments, such as SCI, the magnitude of response seen with NVG-291 treatment has never been seen before.

    https://pharmashots.com/66471/pharmashots-interview-paul-brennan-shares-insights-on-nvg-291-and-its-interim-data-for-the-treatment-of-neurodegenerative-diseases/
  • M
    Mark
    What's going on? Why the sudden drop?
  • L
    Lost it
    Good movement here. Slow buying says someone is excited.
  • J
    John
    NervGen (NGENF): New Alzheimer drug could have ‘blockbuster potential

     Are there any other developments on the horizon that you can tell us about? 

    • Presenting preclinical data in stroke, chronic spinal cord injury and Alzheimer's disease models; all of which could represent completely new treatment paradigms 

    • Updates on the progress of the multiple ascending (MAD) portion of our ongoing Phase 1 study

     • Removal of the ongoing partial clinical hold, initiation of Phase 1 bridging studies and reporting of results on bridging studies

    • Initiation of Phase 1b/2 study in Alzheimer’s disease

     • Initiation of Phase 2 study in MS 

    • Initiation of Phase 1b/2 study in spinal cord injury 

    • Awarding of non-dilutive grants to support our research activities, which if successful could come from the US DoD [Department of Defense] or from private sources.

    "Our platform technology has the potential to restore the function and therapeutic outcomes for all central nervous system damage, including multiple sclerosis, Alzheimer’s disease, spinal cord injury, stroke and traumatic brain injury,” Paul Brennan, president and CEO of NervGen.

    Amazing Efficacy in animals during trials.

    NervGEN NGENF Elevator Summary Here

    https://wp.me/p33WjT-2
  • C
    Charlie
    The January 14 2022 NervGEN webcast---Focus is on Spinal Cord Injury

    NervGEN Unleashing the Nervous System to Repair and  Heal Itself- including multiple sclerosis (MS), Alzheimer’s disease, spinal cord injury, stroke and traumatic brain injury (TBI).

    https://biopub-webcasts.s3.amazonaws.com/January+14%2C+2022%3A+NervGen's+Fresh+Take+on+the+Silver+Cord
  • J
    Jeff
    Good news today. I'm a buyer here.
  • J
    John
    August 12, 2021 Unleashing the Nervous System to Heal Itself 

    8 minutes 53 seonds to 9:18 CEO Paul Brennan  talks about NervGEN technology being applicable to ALL Central Nervous System Diseases  

    26:20 NervGEN NVG-291 34:20 Slide 14 Neurodegenerative diseases Parkinson's NVG-291 has the potential to treat ALL CENTRAL NERVOUS DISEASES 

    See Mice Given NervGEN Drug NVG-291 

    9:24  Spinal Cord Injury

    41:02 Spinal Cord Injury55.18  MS  

    NervGEN Pharma Zoom Presentation

      https://www.youtube.com/watch?v=INWe40Kb8gQ
    NervGen Pharma Zoom Presentation - August 12, 2021
    www.youtube.com
  • J
    John
    Dr George Perry founding Editor-in-Chief of the Journal of Alzheimer’s Disease on NervGEN Alzheimer's Advisory Board

    https://www.nervgen.com/2021/01/nervgen-pharma-establishes-alzheimers-disease-scientific-advisory-board/

    “I am excited about the potential of NVG-291,” stated Dr. George Perry. “The technology has a unique pharmacological profile, which is very different from other products in preclinical and clinical development in that it focuses on restoring function. The Advisory Board members that have been assembled by NervGen are world renowned Alzheimer’s disease researchers and are well positioned to provide the Company with the guidance it needs to maximize the chance of success in its studies.”

    Dr. George Perry, PhD, is the current and founding Editor-in-Chief of the Journal of Alzheimer’s Disease and Semmes Distinguished University Chair in Neurobiology at the University of Texas, San Antonio. He received his Bachelor of Arts degree in Zoology from University of California, Santa Barbara and his PhD in Marine Biology from the Scripps Institute of Oceanography, University of California, San Diego. Dr. Perry has received a number of awards for his research in the Alzheimer’s disease space, including the Denham Harman Research Award, the Senior Investigator Award from the College of Geriatric Psychoneuropharmacology and the Zenith and Temple Awards from the Alzheimer’s Association.
    Vancouver, Canada. January 26, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today
    Vancouver, Canada. January 26, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today
    www.nervgen.com
  • A
    AuriniaBeach
    An in depth look at NervGen and its lead agent NVG-291, with CEO Paul Brennan: BioPub.co Presents: Maximizing Value, NervGen’s Indication Strategy and Operational Update. Just search yuotube “BioPub NervGen”. 12/16/2020 Webcast.